Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Myeloid 1

Conditions

Melanoma 65Neoplasms 29Neoplasm Metastasis 11Thyroid Neoplasms 10Thyroid Carcinoma, Anaplastic 9Glioma 9Brain Neoplasms 9Multiple Myeloma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Hematologic Neoplasms 6Thyroid Cancer, Papillary 4Skin Neoplasms 4Ameloblastoma 4Histiocytosis, Langerhans-Cell 3Glioblastoma 3Astrocytoma 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Ganglioneuroma 2

Interventions

trametinib 2dabrafenib 2antineoplaston AS 2-1 2antineoplaston A10 2mirdametinib 1Vincristine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neurocytoma × dabrafenib × Clear all
NCT03975829 2026-05-11

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡